114 related articles for article (PubMed ID: 14627502)
1. Inhibitory effect of curcumin on proliferation of K562 cells involves down-regulation of p210(bcr/abl) initiated Ras signal transduction pathway.
Wu LX; Xu JH; Wu GH; Chen YZ
Acta Pharmacol Sin; 2003 Nov; 24(11):1155-60. PubMed ID: 14627502
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
[TBL] [Abstract][Full Text] [Related]
3. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells.
Zhang KZ; Xu JH; Huang XW; Wu LX; Su Y; Chen YZ
Acta Pharmacol Sin; 2007 Jan; 28(1):105-10. PubMed ID: 17184589
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of tumor promoters on P210bcr-abl expression.
Li WJ; Smith LA; Kabat KG; Kloetzer WS; Arlinghaus RB
Hematol Pathol; 1989; 3(3):113-23. PubMed ID: 2687223
[TBL] [Abstract][Full Text] [Related]
5. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
Zhang K; Xu J; Huang X; Wu L; Wen C; Hu Y; Su Y; Chen Y; Zhang Z
Cancer Chemother Pharmacol; 2007 Sep; 60(4):581-7. PubMed ID: 17435997
[TBL] [Abstract][Full Text] [Related]
6. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
7. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
Bártová E; Harnicarová A; Pacherník J; Kozubek S
Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
9. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
11. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
[TBL] [Abstract][Full Text] [Related]
12. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
13. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
15. Human stem cell model to study signal transduction and molecular regulation mechanisms in CML.
Fan E; Hu Y; Zhao C
Chin Med J (Engl); 2001 Jul; 114(7):680-4. PubMed ID: 11780326
[TBL] [Abstract][Full Text] [Related]
16. [Effect of curcumin on STAT5 signaling molecule in K562 cells].
Chen WH; Chen Y; Gu JX; He J
Zhonghua Xue Ye Xue Za Zhi; 2004 Mar; 25(3):151-3. PubMed ID: 15182583
[TBL] [Abstract][Full Text] [Related]
17. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
18. Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells.
Chen J; Bai H; Wang C; Kang J
Pharmazie; 2006 Aug; 61(8):710-6. PubMed ID: 16964716
[TBL] [Abstract][Full Text] [Related]
19. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
20. [Regulation of protein kinases on signal pathway in breast cancer cell MCF-7 by curcumin].
Zhou QM; Su SB; Zhang H; Lu YY
Zhong Yao Cai; 2009 May; 32(5):728-32. PubMed ID: 19771847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
